[{"address1": "One Amgen Center Drive", "city": "Thousand Oaks", "state": "CA", "zip": "91320-1799", "country": "United States", "phone": "805 447 1000", "fax": "805 447 1010", "website": "https://www.amgen.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh\u00e7et's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.", "fullTimeEmployees": 26700, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert A. Bradway", "age": 61, "title": "Chairman, CEO & President", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 6731433, "exercisedValue": 0, "unexercisedValue": 64735872}, {"maxAge": 1, "name": "Mr. Peter H. Griffith", "age": 65, "title": "Executive VP & CFO", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 3069385, "exercisedValue": 0, "unexercisedValue": 1429055}, {"maxAge": 1, "name": "Mr. Esteban  Santos", "age": 56, "title": "Executive Vice President of Operations", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 3006074, "exercisedValue": 0, "unexercisedValue": 12988893}, {"maxAge": 1, "name": "Dr. David M. Reese M.D.", "age": 61, "title": "Executive VP & CTO", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 3402742, "exercisedValue": 0, "unexercisedValue": 9008793}, {"maxAge": 1, "name": "Mr. Murdo  Gordon", "age": 57, "title": "Executive Vice President of Global Commercial Operations", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 3243134, "exercisedValue": 0, "unexercisedValue": 5928890}, {"maxAge": 1, "name": "Mr. Matthew C. Busch", "age": 50, "title": "Chief Accounting Officer & VP of Finance", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Scott  Skellenger", "title": "Senior VP & Chief Information Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Howard Y. Chang M.D., Ph.D.", "title": "Senior VP of Global Research & Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Justin G. Claeys", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan P. Graham J.D.", "age": 63, "title": "Executive VP, General Counsel & Secretary", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 2440307, "exercisedValue": 0, "unexercisedValue": 2105468}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 2, "shareHolderRightsRisk": 1, "overallRisk": 3, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-IRHome", "maxAge": 86400, "priceHint": 2, "previousClose": 264.21, "open": 260.79, "dayLow": 260.55, "dayHigh": 264.79, "regularMarketPreviousClose": 264.21, "regularMarketOpen": 260.79, "regularMarketDayLow": 260.55, "regularMarketDayHigh": 264.79, "dividendRate": 9.52, "dividendYield": 0.0363, "exDividendDate": 1739491200, "payoutRatio": 1.1341001, "fiveYearAvgDividendYield": 2.98, "beta": 0.599, "trailingPE": 33.447704, "forwardPE": 12.641423, "volume": 2685459, "regularMarketVolume": 2685459, "averageVolume": 3415855, "averageVolume10days": 2712250, "averageDailyVolume10Day": 2712250, "bid": 261.97, "ask": 262.4, "bidSize": 300, "askSize": 200, "marketCap": 140957286400, "fiftyTwoWeekLow": 253.3, "fiftyTwoWeekHigh": 346.85, "priceToSalesTrailing12Months": 4.332615, "fiftyDayAverage": 283.128, "twoHundredDayAverage": 304.2569, "trailingAnnualDividendRate": 8.88, "trailingAnnualDividendYield": 0.03360963, "currency": "USD", "enterpriseValue": 192344211456, "profitMargins": 0.13002, "floatShares": 536043757, "sharesOutstanding": 537532992, "sharesShort": 11534229, "sharesShortPriorMonth": 9805318, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.0215, "heldPercentInsiders": 0.00213, "heldPercentInstitutions": 0.81152, "shortRatio": 2.55, "shortPercentOfFloat": 0.0215, "impliedSharesOutstanding": 537532992, "bookValue": 14.004, "priceToBook": 18.725365, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "earningsQuarterlyGrowth": 0.636, "netIncomeToCommon": 4230000128, "trailingEps": 7.84, "forwardEps": 20.67, "lastSplitFactor": "2:1", "lastSplitDate": 943228800, "enterpriseToRevenue": 5.912, "enterpriseToEbitda": 15.705, "52WeekChange": -0.13592327, "SandP52WeekChange": 0.22263205, "lastDividendValue": 2.25, "lastDividendDate": 1731888000, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AMGN", "underlyingSymbol": "AMGN", "shortName": "Amgen Inc.", "longName": "Amgen Inc.", "firstTradeDateEpochUtc": 424704600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "9376b97e-b428-3231-ba0b-142b20481cb4", "messageBoardId": "finmb_24816", "gmtOffSetMilliseconds": -18000000, "currentPrice": 262.23, "targetHighPrice": 405.0, "targetLowPrice": 195.0, "targetMeanPrice": 317.2369, "targetMedianPrice": 313.5, "recommendationMean": 2.40625, "recommendationKey": "buy", "numberOfAnalystOpinions": 26, "totalCash": 9011000320, "totalCashPerShare": 16.764, "ebitda": 12247000064, "totalDebt": 60397998080, "quickRatio": 0.804, "currentRatio": 1.318, "totalRevenue": 32533999616, "debtToEquity": 802.418, "revenuePerShare": 60.641, "returnOnAssets": 0.04597, "returnOnEquity": 0.5572, "freeCashflow": 4574875136, "operatingCashflow": 7256999936, "earningsGrowth": 0.621, "revenueGrowth": 0.232, "grossMargins": 0.60589004, "ebitdaMargins": 0.37644002, "operatingMargins": 0.24156, "financialCurrency": "USD", "trailingPegRatio": 1.8659, "__fetch_time": "2025-01-11"}]